|Home||» Products||» Active Pharmaceutical Ingredients (API)||» Voglibose|
Capitalizing on the proficiency of our professionals, we have been able to manufacture and export an unparalleled range of Voglibose. These drugs are prescribed for lowering post-prandial blood glucose levels in patients suffering with diabetes mellitus. Our Voglibose is processed from top quality ingredients at our state of the art machining facility, under the observation of veteran experts & pharmacists. We follow the parameters of the national and international quality standards to offer our clients with utmost pleasure in terms of quality.
IUPAC Name : (1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetraol
CAS Number :83480-29-9
Innovator : It is a research product of Takeda Pharma, a Japan-based company.
Therapeutic Category: Antidiabetics
Indication : Voglibose delays the absorption of glucose thereby reduces the risk of macrovascular complications
Dosage: Single dose of 0.2mg, given three times a day
It is an alpha-glucosidase inhibitor
Mechanism of Action:
Postprandial hyperglycemia (PPHG) is primarily due to first phase insulin secretion. Alpha glucosidase inhibitors delay glucose absorption at the intestine level and thereby prevent sudden surge of glucose after a meal.
Advog 0.2 mg Eris Lifescience.
Voglase 0.2mg Wockhardt Ltd.
Vobose 0.3mg USV
Voglitab 0.3 mg Intas Pharmaceuticals